Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Frontiers in Neurology|September 20, 2024
Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panelSabina Cevoli, Piero Barbanti, Cinzia Finocchi, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
Journal of Neurology|January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE studyPiero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2026
Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in ItalyPiero Barbanti, Cristina Tassorelli, Fabrizio Vernieri, et al.
Neurosurgical Focus|July 1, 2021
Mechanical thrombectomy in acute ischemic stroke with tandem occlusions: impact of extracranial carotid lesion etiology on endovascular management and outcomeValerio Da Ros, Jacopo Scaggiante, Francesca Pitocchi, et al.
European Journal of Neurology|September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT studyFabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 3, 2022
The PRESTO study: awareness of stroke symptoms and time from onset to interventionIlaria Gandoglia, Erika Schirinzi, Mehrnaz Hamedani, et al.
The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Pageof 6